PIJ.MU - Platinum Asset Management Ltd
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 1.0700 |
| Open | 1.0700 |
| Bid | 1.0200 x 0 |
| Ask | 1.0700 x 0 |
| Day's Range | 1.0700 - 1.0700 |
| 52 Week Range | 1.0400 - 1.4500 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
Simply Wall St.While insiders own 28% of Platinum Investment Management Limited (ASX:PTM), retail investors are its largest shareholders with 47% ownership
Key Insights Significant control over Platinum Investment Management by retail investors implies that the general...
Insider MonkeyAustralian Billionaire Kerr Neilson is Selling These 15 Stocks
In this article, we discuss the 15 stocks Australian billionaire Kerr Neilson is selling. If you want to skip our analysis of Neilson’s history and investment philosophy, go directly to Australian Billionaire Kerr Neilson is Selling These 15 Stocks. Kerr Neilson is a billionaire investor who co-founded Platinum Asset Management with Andrew Clifford nearly 28 […]
- Simply Wall St.
Platinum Investment Management Limited's (ASX:PTM) largest shareholders are individual investors with 49% ownership, insiders own 28%
Every investor in Platinum Investment Management Limited ( ASX:PTM ) should be aware of the most powerful shareholder...
- Simply Wall St.
Platinum Investment Management (ASX:PTM) investors are sitting on a loss of 57% if they invested five years ago
We think intelligent long term investing is the way to go. But unfortunately, some companies simply don't succeed...
GlobeNewswireargenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measuresEuropean Commission decision on marketing authorization application (MAA) expected in approximately 60 days If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG) Breda, the Netherlands—June 24, 2022—argenx (Eur